Vorinostat (Zolinza) News and Research

RSS
Vorinostat is a synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.
Researchers develop new drug-testing platform for epilepsy

Researchers develop new drug-testing platform for epilepsy

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

FDA accepts IND for Arno Therapeutics' Pan-DAC / Akt inhibitor, AR-42

FDA accepts IND for Arno Therapeutics' Pan-DAC / Akt inhibitor, AR-42

New data on ZOLINZA (vorinostat) in combination with Bortezomib

New data on ZOLINZA (vorinostat) in combination with Bortezomib

New way to treat advanced prostate cancer, potentially more effective, fewer side effects

New way to treat advanced prostate cancer, potentially more effective, fewer side effects

Potential new way to prevent graft-versus-host disease

Potential new way to prevent graft-versus-host disease

Study results from Zolinza (vorinostat) in combination with bortezomib for multiple myeloma trial

Study results from Zolinza (vorinostat) in combination with bortezomib for multiple myeloma trial

New molecules discovered that block cancer cells from modifying cell DNA

New molecules discovered that block cancer cells from modifying cell DNA

Vorinostat shows anti-cancer activity in recurrent gliomas

Vorinostat shows anti-cancer activity in recurrent gliomas

ESMO explores collaboration to fight cancer on all fronts

ESMO explores collaboration to fight cancer on all fronts

FDA approves Zolinza for the treatment of cutaneous T-cell lymphoma

FDA approves Zolinza for the treatment of cutaneous T-cell lymphoma